RenovaroCube to acquire remaining 25% of Cyclomics for 100% ownership in cancer diagnostics

Lunai Bioworks Inc.

RenovaroCube amends LOI to acquire full 100% ownership of Cyclomics (was 75%).
Deal strengthens AI-driven early cancer detection; combines CyclomicsSeq and OmniOmics 4th-gen tech.
Collaborations with Oxford Nanopore and Nvidia provide sequencing, supercomputing, and AI software.
Technology aims to detect a single ctDNA molecule in blood with nearly 100% accuracy.
RenovaroCube's Cube platform has over 3,600 biomarker panels for 13 cancers.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.